Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial

PartnershipARCT-032Positive

AI Analysis

Summary

Thermo Fisher and Arcturus Therapeutics announced a strategic collaboration agreement for Phase III development of ARCT-032, an investigational therapy for cystic fibrosis.

Clinical Trial Data

Phase

Phase III

Importance:7/10

Sentiment:

0.40

cystic fibrosisgene therapyclinical developmentstrategic partnership

Related Companies

$ARCT

Read the original article

Published by Clinical Trials Arena on July 3, 2026 7:31 AM

Read Original